Jazz Pharmaceuticals JAZZ Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accounts payable?
- Jazz Pharmaceuticals (JAZZ) reported accounts payable of $100M in Q1 2026.
- How has Jazz Pharmaceuticals's accounts payable changed year-over-year?
- Jazz Pharmaceuticals's accounts payable increased by 4.2% year-over-year, from $95.93M to $100M.
- What is the long-term trend for Jazz Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accounts payable has grown at a 35.3% compound annual growth rate (CAGR), from $26.95M to $122.1M.
- What does accounts payable mean?
- Money owed to suppliers for goods and services received.
- How do you interpret accounts payable?
- An increase may signal improved cash management or delayed payments, while a decrease may indicate faster settlement of obligations.
- How does accounts payable compare across companies?
- Commonly compared via Days Payable Outstanding (DPO) to benchmark against industry peers.